• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pulmonary therapy. >Severe Asthma and Biological Therapy: When, Which, and for Whom
【24h】

Severe Asthma and Biological Therapy: When, Which, and for Whom

机译：严重的哮喘和生物治疗：当，哪些和为谁

获取原文
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Asthma is a heterogeneous chronic inflammatory disease of the airways that affects approximately 300 million people worldwide. About 5–10% of all asthmatics suffer from severe or uncontrolled asthma, associated with increased mortality and hospitalization, reduced quality of life, and increased health care costs. In recent years, new treatments have become available, and different asthma phenotypes characterized by specific biomarkers have been identified. Biological drugs are currently indicated for patients with severe asthma that is not controlled with recommended treatments. They are mostly directed against inflammatory molecules of the type 2 inflammatory pathway and are effective at reducing exacerbations, maintaining control over asthma symptoms, and reducing systemic steroid use, which is associated with well-known adverse events. Although biological drugs for severe asthma have had a major impact on the management of the disease, there is still a need for head-to-head comparison studies of biologics and to identify new biomarkers for asthma diagnosis, prognosis, and response to treatment.?Identifying novel biomarkers could facilitate the development of therapeutic strategies that are precisely tailored to each patient’s requirements.
机译：哮喘是气道的异质慢性炎症疾病，影响全世界约有3亿人。约5-10％的哮喘患者患有严重或不受控制的哮喘，与增加的死亡率和住院，减少生活质量和养生费用增加。近年来，新的治疗可用，并且已经确定了特异性生物标志物特征的不同哮喘表型。目前针对哮喘严重哮喘的患者表明了生物药物，其不受推荐治疗的严重哮喘。它们主要针对2型炎症途径的炎症分子，并且有效地减少加剧，维持对哮喘症状的控制，以及减少与众所周知的不良事件相关的全身类固醇使用。虽然严重哮喘的生物药物对疾病的管理产生了重大影响，但仍然需要对生物学的头脑比较研究，并鉴定哮喘诊断，预后和对治疗的反应的新生物标志物。？识别新型生物标志物可以促进对每位患者的要求准确定制的治疗策略的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号